Linscomb Wealth’s AbbVie ABBV Stock Holding History

Linscomb Wealth’s Portfolio ABBV Stock Details ABBV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$16.9M	Sell	77,674 -9,796	-11%	-$2.17M	0.75%	21
2025 Q4	$20M	Sell	87,470 -1,240	-1%	-$282K	0.84%	16
2025 Q3	$20.5M	Sell	88,710 -1,455	-2%	-$296K	0.88%	17
2025 Q2	$16.7M	Buy	90,165 +2,928	+3%	+$544K	0.77%	17
2025 Q1	$18.3M	Buy	87,237 +8,826	+11%	+$1.72M	0.91%	15
2024 Q4	$13.9M	Buy	78,411 +48	+0.1%	+$8.82K	0.69%	18
2024 Q3	$15.5M	Sell	78,363 -2,653	-3%	-$495K	0.77%	17
2024 Q2	$13.9M	Sell	81,016 -200	-0.2%	-$33.1K	0.72%	19
2024 Q1	$14.8M	Sell	81,216 -2,465	-3%	-$425K	0.76%	19
2023 Q4	$13M	Sell	83,681 -2,102	-2%	-$306K	0.71%	19
2023 Q3	$12.8M	Sell	85,783 -4,368	-5%	-$641K	0.75%	17
2023 Q2	$12.1M	Sell	90,151 -4,379	-5%	-$642K	0.66%	23
2023 Q1	$15.1M	Sell	94,530 -4,902	-5%	-$749K	0.79%	15
2022 Q4	$16.1M	Buy	99,432 +5,218	+6%	+$800K	0.82%	15
2022 Q3	$12.6M	Sell	94,214 -484	-0.5%	-$69.5K	0.77%	15
2022 Q2	$14.5M	Sell	94,698 -6,782	-7%	-$1.04M	0.83%	14
2022 Q1	$16.5M	Buy	101,480 +2,295	+2%	+$333K	0.79%	15
2021 Q4	$13.4M	Buy	99,185 +922	+0.9%	+$109K	0.64%	29
2021 Q3	$10.6M	Buy	98,263 +1,809	+2%	+$207K	0.55%	39
2021 Q2	$10.9M	Buy	96,454 +2,689	+3%	+$303K	0.56%	39
2021 Q1	$10.1M	Buy	93,765 +1,036	+1%	+$111K	0.55%	40
2020 Q4	$9.94M	Buy	92,729 +2,173	+2%	+$209K	0.59%	33
2020 Q3	$7.93M	Buy	90,556 +3,287	+4%	+$309K	0.55%	42
2020 Q2	$8.57M	Buy	87,269 +11,184	+15%	+$985K	0.63%	28
2020 Q1	$5.8M	Buy	76,085 +4,627	+6%	+$394K	0.51%	36
2019 Q4	$6.33M	Buy	71,458 +1,605	+2%	+$133K	0.41%	40
2019 Q3	$5.29M	Buy	69,853 +5,885	+9%	+$403K	0.43%	45
2019 Q2	$4.65M	Buy	63,968 +694	+1%	+$54.5K	0.38%	49
2019 Q1	$5.1M	Buy	63,274 +1,684	+3%	+$138K	0.43%	40
2018 Q4	$5.68M	Sell	61,590 -879	-1%	-$77.3K	0.54%	33
2018 Q3	$5.91M	Sell	62,469 -479	-0.8%	-$45.4K	0.49%	32
2018 Q2	$5.83M	Buy	62,948 +1,715	+3%	+$167K	0.5%	26
2018 Q1	$5.8M	Sell	61,233 -655	-1%	-$72K	0.49%	29
2017 Q4	$5.99M	Sell	61,888 -1,147	-2%	-$108K	0.49%	29
2017 Q3	$5.6M	Buy	63,035 +228	+0.4%	+$17.4K	0.48%	28
2017 Q2	$4.55M	Buy	62,807 +786	+1%	+$52.8K	0.41%	36
2017 Q1	$4.04M	Buy	62,021 +4,889	+9%	+$307K	0.37%	43
2016 Q4	$3.58M	Buy	57,132 +2,549	+5%	+$156K	0.33%	46
2016 Q3	$3.44M	Buy	54,583 +4,650	+9%	+$301K	0.33%	45
2016 Q2	$3.09M	Sell	49,933 -317	-0.6%	-$19.3K	0.31%	45
2016 Q1	$2.87M	Buy	50,250 +867	+2%	+$48.3K	0.31%	53
2015 Q4	$2.92M	Buy	49,383 +1,491	+3%	+$85.9K	0.33%	47
2015 Q3	$2.61M	Buy	47,892 +773	+2%	+$50.3K	0.31%	52
2015 Q2	$3.17M	Sell	47,119 -33	-0.1%	-$2.15K	0.35%	44
2015 Q1	$2.76M	Buy	47,152 +894	+2%	+$54K	0.3%	56
2014 Q4	$3.03M	Buy	46,258 +1,268	+3%	+$79.9K	0.34%	49
2014 Q3	$2.6M	Buy	44,990 +1,010	+2%	+$56.1K	0.29%	54
2014 Q2	$2.48M	Buy	43,980 +1,312	+3%	+$68.8K	0.26%	56
2014 Q1	$2.19M	Buy	42,668 +4,829	+13%	+$244K	0.24%	59
2013 Q4	$2M	Buy	37,839 +336	+0.9%	+$16.5K	0.25%	57
2013 Q3	$1.68M	Buy	37,503 +539	+1%	+$23.9K	0.22%	56
2013 Q2	$1.53M	Buy	+36,964	New	+$1.62M	0.21%	58

Other funds holding ABBV

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Linscomb Wealth's ABBV Position: Q1 2026 in Review

Linscomb Wealth reduced its AbbVie (ABBV) stake by 11% in Q1 2026, selling an estimated $2.17M and leaving 77,674 shares worth $16.9M. The position accounts for 0.75% of the portfolio, ranked #21.

Linscomb Wealth first reported a position in ABBV in Q2 2013 and has held it in 52 quarters since. The position peaked at $20.5M in Q3 2025. 4,076 funds tracked by Wall St. Rank hold ABBV as of Q1 2026.

Linscomb Wealth held 77,674 shares of AbbVie worth $16.9M as of Q1 2026.
Linscomb Wealth sold 9,796 AbbVie shares in Q1 2026, an estimated $2.17M.
AbbVie made up 0.75% of Linscomb Wealth's portfolio in Q1 2026, its #21 holding.
Linscomb Wealth first reported a position in AbbVie in Q2 2013 and has held it in 52 quarters since.
Linscomb Wealth's AbbVie position peaked at $20.5M in Q3 2025.
4,076 funds tracked by Wall St. Rank held AbbVie as of Q1 2026.

Based on Linscomb Wealth's 13F filing for Q1 2026, filed 11 May 2026.